BR0307278A - Formulação oral de liberação imediata, e, método para preparar uma formulação - Google Patents
Formulação oral de liberação imediata, e, método para preparar uma formulaçãoInfo
- Publication number
- BR0307278A BR0307278A BR0307278-9A BR0307278A BR0307278A BR 0307278 A BR0307278 A BR 0307278A BR 0307278 A BR0307278 A BR 0307278A BR 0307278 A BR0307278 A BR 0307278A
- Authority
- BR
- Brazil
- Prior art keywords
- formulation
- amount
- immediate release
- total weight
- preparing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"FORMULAçãO ORAL DE LIBERAçãO IMEDIATA, E, MéTODO PARA PREPARAR UMA FORMULAçãO". A presente invenção refere-se a uma formulação de liberação imediata com biodisponibilidade aumentada compreendendo uma solução homogênea e termoestável de uma substância biologicamente ativa deficientemente solúvel em água, em que a referida solução é composta de :a) a substância ativa em uma quantidade entre 10 e 50% do peso total da formulação, b) um tensoativo hidrofílico não iónico, que está na forma líquida entre 15 e 30<198>C, em uma quantidade entre 20% e 70% do peso total da formulação e c) um polimero orgânico ou mistura de polímeros orgânicos farmaceuticamente aceitável, sendo que o polímero ou mistura de polímeros está em forma líquida acima de 60<198>C e em forma sólida abaixo de 30<198>C, em uma quantidade entre 5% e 70% do peso total da formulação, e d) opcionalmente, um agente de desintegração em uma quantidade entre 1% e 10% do peso total da formulação. A invenção refere-se adicionalmente a substâncias ativas formuladas na forma acima e a métodos para produzir a formulação.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02075623 | 2002-02-14 | ||
| PCT/EP2003/050014 WO2003068266A1 (en) | 2002-02-14 | 2003-02-11 | Oral solid solution formulation of a poorly water-soluble active substance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0307278A true BR0307278A (pt) | 2004-12-28 |
Family
ID=27619166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0307278-9A BR0307278A (pt) | 2002-02-14 | 2003-02-11 | Formulação oral de liberação imediata, e, método para preparar uma formulação |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20050008697A1 (pt) |
| EP (1) | EP1476196B1 (pt) |
| JP (1) | JP2005517041A (pt) |
| KR (1) | KR101014545B1 (pt) |
| CN (1) | CN1273194C (pt) |
| AR (1) | AR038681A1 (pt) |
| AT (1) | ATE345817T1 (pt) |
| AU (1) | AU2003208713B2 (pt) |
| BR (1) | BR0307278A (pt) |
| CA (1) | CA2472744A1 (pt) |
| DE (1) | DE60309839T2 (pt) |
| DK (1) | DK1476196T3 (pt) |
| ES (1) | ES2277635T3 (pt) |
| HK (1) | HK1077218A1 (pt) |
| HR (1) | HRP20040613A2 (pt) |
| IL (2) | IL162883A0 (pt) |
| MX (1) | MXPA04007852A (pt) |
| NO (1) | NO20043832L (pt) |
| PL (1) | PL370452A1 (pt) |
| PT (1) | PT1476196E (pt) |
| RU (1) | RU2314811C2 (pt) |
| SI (1) | SI1476196T1 (pt) |
| UA (1) | UA79267C2 (pt) |
| WO (1) | WO2003068266A1 (pt) |
| ZA (1) | ZA200405608B (pt) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004062692A1 (en) * | 2003-01-13 | 2004-07-29 | Solvay Pharmaceuticals B.V. | Formulation of poorly water-soluble active substances |
| US8025899B2 (en) * | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| US8377952B2 (en) * | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| US20050267124A1 (en) * | 2004-05-14 | 2005-12-01 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors |
| US20060159748A1 (en) * | 2004-12-23 | 2006-07-20 | Rajesh Jain | Oral immediate release formulation of a poorly water-soluble active substance |
| TW200633713A (en) * | 2004-12-23 | 2006-10-01 | Solvay Pharm Bv | Oral immediate release formulation of a poorly water-soluble active substance |
| WO2007054975A1 (en) * | 2005-11-08 | 2007-05-18 | Panacea Biotec Ltd | Pharmaceutical compositions for the treatment of cardiovascular and other associated disorders |
| US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| JP2007308479A (ja) | 2006-04-20 | 2007-11-29 | Shin Etsu Chem Co Ltd | 固体分散体製剤 |
| ATE509620T1 (de) * | 2006-06-16 | 2011-06-15 | Abbott Healthcare Products Bv | Orale pharmazeutische zusammensetzung einer schwer wasserlöslichen wirksubstanz |
| EP2037890A1 (en) * | 2006-06-22 | 2009-03-25 | Solvay Pharmaceuticals B.V. | Oral pharmaceutical composition of a poorly water-soluble active substance |
| EP2037897B1 (en) * | 2006-07-06 | 2011-03-30 | Ares Trading S.A. | An oral pharmaceutical composition of an anilinopyrimidine, its preparation and use thereof |
| WO2008027522A2 (en) * | 2006-09-01 | 2008-03-06 | Teva Pharmaceutical Industries Ltd. | Solid composites of a calicum receptor-active compound |
| AR071375A1 (es) * | 2008-04-22 | 2010-06-16 | Solvay Pharm Gmbh | Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto |
| EP2440210A4 (en) | 2009-06-12 | 2014-01-29 | Meritage Pharma Inc | METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES |
| RS58017B1 (sr) | 2010-08-04 | 2019-02-28 | Gruenenthal Gmbh | Farmaceutska dozna forma koja sadrži 6'-fluoro-(n-metil- ili n,n-dimetil-)-4-fenil-4',9'-dihidro-3'h-spiro[cikloheksan-1,1'-pirano[3,4,b]indol]-4-amin za lečenje nociceptivnog bola |
| ES2665344T3 (es) * | 2010-08-04 | 2018-04-25 | Grünenthal GmbH | Forma de dosificacion farmaceutica que comprende 6'-fluor-(N-metil- o N,N-dimetil-)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina |
| WO2017004733A1 (zh) * | 2015-07-03 | 2017-01-12 | 浙江海正药业股份有限公司 | 一种人参皂苷c-k口服固体制剂及其制备方法 |
| PL424452A1 (pl) | 2018-01-31 | 2019-08-12 | Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu |
| ES2943492T3 (es) | 2018-11-30 | 2023-06-13 | Chemocentryx Inc | Formulación de cápsulas |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3359167A (en) * | 1965-07-22 | 1967-12-19 | Pfizer & Co C | Vitamin a compositions |
| CU35543A1 (es) * | 1980-10-09 | 1983-05-05 | Hoffmann La Roche | Prostaglandines |
| NZ224497A (en) * | 1987-05-18 | 1990-04-26 | Janssen Pharmaceutica Nv | Pharmaceutical composition comprising flunarizine |
| US5281420A (en) * | 1992-05-19 | 1994-01-25 | The Procter & Gamble Company | Solid dispersion compositions of tebufelone |
| DE19510566A1 (de) * | 1995-03-23 | 1996-09-26 | Kali Chemie Pharma Gmbh | Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DE19638020A1 (de) * | 1996-09-18 | 1998-03-19 | Solvay Pharm Gmbh | Die gastrointestinale Durchblutung fördernde Arzneimittel |
| TW426516B (en) * | 1996-12-06 | 2001-03-21 | Fujisawa Pharmaceutical Co | An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds |
| US6475519B1 (en) * | 1997-01-30 | 2002-11-05 | Novartis Ag | Oil-free pharmaceutical compositions containing cyclosporin A |
| US6008191A (en) * | 1997-09-08 | 1999-12-28 | Panacea Biotec Limited | Pharmaceutical compositions containing cyclosporin |
| KR100336090B1 (ko) * | 1998-06-27 | 2002-05-27 | 윤승원 | 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제 |
| DE19906310A1 (de) * | 1999-02-16 | 2000-08-17 | Solvay Pharm Gmbh | Arzneimittel zur Behandlung von Bluthochdruck |
| DE19932555A1 (de) * | 1999-07-13 | 2001-01-18 | Solvay Pharm Gmbh | Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen |
| US20010036959A1 (en) * | 2000-04-03 | 2001-11-01 | Gabel Rolf Dieter | Carvedilol-hydrophilic solutions |
-
2003
- 2003-02-04 AR ARP030100341A patent/AR038681A1/es unknown
- 2003-02-11 BR BR0307278-9A patent/BR0307278A/pt not_active Application Discontinuation
- 2003-02-11 PT PT03706620T patent/PT1476196E/pt unknown
- 2003-02-11 JP JP2003567446A patent/JP2005517041A/ja active Pending
- 2003-02-11 SI SI200330630T patent/SI1476196T1/sl unknown
- 2003-02-11 WO PCT/EP2003/050014 patent/WO2003068266A1/en active IP Right Grant
- 2003-02-11 DK DK03706620T patent/DK1476196T3/da active
- 2003-02-11 AT AT03706620T patent/ATE345817T1/de active
- 2003-02-11 KR KR1020047012635A patent/KR101014545B1/ko not_active IP Right Cessation
- 2003-02-11 IL IL16288303A patent/IL162883A0/xx unknown
- 2003-02-11 DE DE60309839T patent/DE60309839T2/de not_active Expired - Lifetime
- 2003-02-11 RU RU2004127457/15A patent/RU2314811C2/ru not_active IP Right Cessation
- 2003-02-11 ES ES03706620T patent/ES2277635T3/es not_active Expired - Lifetime
- 2003-02-11 AU AU2003208713A patent/AU2003208713B2/en not_active Ceased
- 2003-02-11 PL PL03370452A patent/PL370452A1/xx not_active IP Right Cessation
- 2003-02-11 MX MXPA04007852A patent/MXPA04007852A/es active IP Right Grant
- 2003-02-11 CN CNB038038978A patent/CN1273194C/zh not_active Expired - Fee Related
- 2003-02-11 CA CA002472744A patent/CA2472744A1/en not_active Abandoned
- 2003-02-11 EP EP03706620A patent/EP1476196B1/en not_active Expired - Lifetime
- 2003-11-02 UA UA20040907457A patent/UA79267C2/uk unknown
-
2004
- 2004-07-06 HR HR20040613A patent/HRP20040613A2/hr not_active Application Discontinuation
- 2004-07-06 IL IL162883A patent/IL162883A/en not_active IP Right Cessation
- 2004-07-14 ZA ZA200405608A patent/ZA200405608B/en unknown
- 2004-08-11 US US10/915,560 patent/US20050008697A1/en not_active Abandoned
- 2004-09-13 NO NO20043832A patent/NO20043832L/no not_active Application Discontinuation
-
2005
- 2005-10-20 HK HK05109356A patent/HK1077218A1/xx not_active IP Right Cessation
-
2010
- 2010-11-12 US US12/945,570 patent/US20110086844A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2314811C2 (ru) | 2008-01-20 |
| NO20043832L (no) | 2004-09-13 |
| DE60309839D1 (de) | 2007-01-04 |
| IL162883A0 (en) | 2005-11-20 |
| SI1476196T1 (sl) | 2007-04-30 |
| AR038681A1 (es) | 2005-01-26 |
| PT1476196E (pt) | 2007-02-28 |
| HK1077218A1 (en) | 2006-02-10 |
| AU2003208713A1 (en) | 2003-09-04 |
| ZA200405608B (en) | 2005-06-24 |
| WO2003068266A1 (en) | 2003-08-21 |
| US20050008697A1 (en) | 2005-01-13 |
| UA79267C2 (en) | 2007-06-11 |
| AU2003208713B9 (en) | 2003-09-04 |
| CA2472744A1 (en) | 2003-08-21 |
| ATE345817T1 (de) | 2006-12-15 |
| US20110086844A1 (en) | 2011-04-14 |
| ES2277635T3 (es) | 2007-07-16 |
| DK1476196T3 (da) | 2007-03-05 |
| HRP20040613A2 (en) | 2005-04-30 |
| PL370452A1 (en) | 2005-05-30 |
| IL162883A (en) | 2009-05-04 |
| EP1476196A1 (en) | 2004-11-17 |
| CN1633307A (zh) | 2005-06-29 |
| AU2003208713B2 (en) | 2007-10-18 |
| EP1476196B1 (en) | 2006-11-22 |
| MXPA04007852A (es) | 2004-10-15 |
| RU2004127457A (ru) | 2005-04-20 |
| KR20040085193A (ko) | 2004-10-07 |
| CN1273194C (zh) | 2006-09-06 |
| DE60309839T2 (de) | 2007-03-15 |
| JP2005517041A (ja) | 2005-06-09 |
| KR101014545B1 (ko) | 2011-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0307278A (pt) | Formulação oral de liberação imediata, e, método para preparar uma formulação | |
| BRPI0515684A (pt) | formulações de cristais injetáveis ativas de longa duração de metabólitos de estradiol, e métodos de utilização das mesmas | |
| BRPI0417287A (pt) | espuma oleosa para uso farmacêutico e cosmético | |
| BR0008590A (pt) | Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto | |
| RS20070511A (en) | Modified release pharmaceutical compositions and processes thereof | |
| BR9808888A (pt) | Formas de dosagem e método de melhorar disfunção erétil masculina | |
| BR0307344A (pt) | Composições farmacêuticas de dispersões amorfas de fármacos e materiais formadores de microfase lipofìlica | |
| BRPI0509708A (pt) | composição de espuma de pimecrolimus contendo glicol de hexileno, opcionalmente álcool de oleil, dimetilisosorbìdeo e/ou triglicerìdeos de cadeia média | |
| BRPI0509659A8 (pt) | Processo para a preparação de uma composição de polímero de dispersão aquosa | |
| ES2178430T3 (es) | Utilizacion de composiciones farmaceuticas gelificables en parodontologia. | |
| BRPI0414907A (pt) | formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas | |
| DE602005025755D1 (de) | Irbesartan enthaltende pharmazeutische zusammensetzung | |
| PE20100265A1 (es) | Nuevas composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion | |
| DE60138468D1 (de) | Cyanophenoxy-carbonsäuren und zusammensetzungen für die freisetzung aktiver substanzen | |
| BR0007360A (pt) | Composição de liberação controlada | |
| AR044200A1 (es) | Composicion de fondaparinux sodico de alta pureza ,un procedimiento de preparacion de esta composicion y composiciones farmaceuticas que la contienen como principio activo | |
| NO20033564L (no) | Ny formulering med modifisert frigivningsvirkning | |
| RS52777B (en) | CURRENT RELEASE THERAPY SYSTEM FOR IMPROVED ORAL ABSORPTION 7 - [(E) -TERT-BUTYLOXYIMINOMETHYL] CAMPTOTECIN | |
| BRPI0513417A (pt) | composição farmacêutica estável, usos de um poliol, e de uma composição, processo para preparar uma composição farmacêutica, e, método para tratar uma condição responsiva à administração de uma anti-histamina | |
| AR018607A1 (es) | Preparacion farmaceutica que en calidad de ingrediente activo contiene levotiroxina sodica, y un procedimiento para su preparacion | |
| DE602005024554D1 (de) | Pharmazeutische zusammensetzung mit amlodipinbesilat und lisinoprildihydrat und herstellungsverfahren dafür | |
| PT1305057E (pt) | Composicao de biomateria microparticular para uso medicinal | |
| BR0312206A (pt) | Formulações de pélete esférico | |
| BRPI0519248A2 (pt) | formulaÇço oral de liberaÇço imediata de um composto ativo, e, mÉtodo para a preparaÇço de uma formulaÇço | |
| BRPI0408805A (pt) | composição farmacêutica contendo complexo de platina e método de fabricação da mesma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |